Last reviewed · How we verify
AVE2635A
AVE2635A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
AVE2635A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | AVE2635A |
|---|---|
| Sponsor | Sanofi |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AVE2635A is designed to bind and modulate multiple immune pathways, likely targeting combinations of checkpoint molecules to overcome immune evasion in cancer. By engaging dual targets, the drug aims to provide synergistic immune activation beyond single-checkpoint inhibition, potentially improving efficacy in difficult-to-treat tumors.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
Key clinical trials
- Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |